drugset / Trial / NCT00003959
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
Phase 1
Completed
1 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: A vaccine made from a person's myelodysplasia cells may make the body build an immune response to kill cancer cells. Combining vaccine therapy with sargramostim may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating patients who have myelodysplastic syndrome.
Timeline
- Start
- 1999-06
- Primary completion
- 2001-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ras peptide cancer vaccine | Vaccine | — | Intravitreal |
| Background | sargramostim | Protein / enzyme biologic | — | Intravitreal |